Physician profile
Scott J Wolfe
NPI 1740215797
$7,716.20
in general payments reported to CMS, 2019-2025
30 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,774 · 2020: $1,709 · 2021: $1,537 · 2022: $984 · 2023: $866 · 2024: $510 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.83 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $963.04 | 2019-2025 | Jardiance |
| Amgen INC. | $793.26 | 2019-2025 | Prolia, Repatha, Otezla |
| Glaxosmithkline, LLC. | $700.63 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $698.23 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $666.80 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $640.51 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $475.96 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $449.84 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $416.31 | 2019-2023 | |
| Abbvie INC. | $307.77 | 2021-2024 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $258.47 | 2020-2025 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $235.41 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.83 | 2019-2021 | |
| Allergan, INC. | $159.31 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $146.17 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $80.68 | 2021-2023 | Myrbetriq |
| Hikma Pharmaceuticals USA | $72.05 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $65.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.56 | 2021 | |
| Radius Health, INC. | $61.67 | 2019 | |
| Supernus Pharmaceuticals, INC. | $58.88 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $23.74 | 2025 | |
| Abbott Laboratories | $23.64 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.17 | 2019 | |
| Exact Sciences Corporation | $19.88 | 2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $18.92 | 2023 | Yupelri |
| Sanofi Pasteur INC. | $18.72 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.46 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $15.09 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $14.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.